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Abstract
 
The functions and fate of antigen-experienced T cells isolated from lymph node or nonlym-
phoid tissues were analyzed in a system involving adoptive transfer of in vitro–activated T cells
into mice. Activated T cells present in the lymph nodes could be stimulated by antigen to di-
vide, produce effector cytokines, and migrate to peripheral tissues. By contrast, activated T cells
that had migrated into nonlymphoid tissues (lung and airway) produced substantial effector cy-
tokines upon antigen challenge, but were completely unable to divide or migrate back to the
lymph nodes. Therefore, activated T cells can undergo clonal expansion in the lymph node,
but are recruited and retained as nondividing cells in nonlymphoid tissues. These distinct regu-
latory events in lymph node and nonlymphoid tissues reveal simple key mechanisms for both
inducing and limiting T cell immunity.
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Introduction
 
The development of an effector T cell immune response
involves a defined sequence of events. The first event in-
volves the delivery of Ag from an exposed tissue site to the
draining lymph node. This initiates the activation of naive
T cells that constantly recirculate from blood to lymph
node via specialized high-walled endothelium (1–3), and
then back to the blood via lymphatic drainage. The final
event that occurs is the differentiation and expansion of
effector and memory T cells. These effector T cells express
new cell surface molecules that allow them to recirculate
back to nonlymphoid tissue sites (3). Here effector T cells
influence with other leukocytes such as eosinophils, mast
cells, neutrophils, and macrophages, to cause inflammation
and to clear Ag.
It is clear that some effector T cells must be retained in
the lymphoid organs to contact B cells and orchestrate hu-
moral responses. However, what has not been delineated is
the response of effector T cells at nonlymphoid tissue sites
when they reencounter Ag. Do they proliferate again, re-
turn to the draining lymph node to proliferate, or simply
carry out effector functions such as cytokine production? In
this study we attempt to determine whether effector T cells
present in nonlymphoid organs display similar functions to
those effector T cells resident in lymph node, after contact
with Ag. We also follow the fate of those cells that enter
nonlymphoid tissues.
We generated populations of in vitro–activated T cells
 
that expressed CD62L
 
med-lo
 
 and CD62L
 
hi
 
 phenotypes,
which, after adoptive transfer, localize to nonlymphoid
tissue and lymph nodes, respectively. When adoptively
transferred mice were challenged with Ag, the activated T
cells in both the nonlymphoid tissues and lymph node pro-
duced effector cytokines within 2 h. Activated T cells in
the lymph node divided extensively after Ag challenge. By
contrast, activated T cells in nonlymphoid tissues, such as
the lung and airway, could not be induced to divide in vivo
under any circumstance, despite being able to divide to the
same antigenic stimulus in vitro. Those activated T cells
resident in the airway remained fully competent with re-
spect to effector cytokine production, but were apparently
unable to return to the draining lymph nodes nor to the
circulating pool of lymphocytes.
 
Materials and Methods
 
Mice. 
 
All mice were bred and maintained at the Animal Fa-
cility of the Wellington School of Medicine (Wellington, New
Zealand). B10.A mice were originally obtained from The Jackson
Laboratory and maintained by brother x sister mating. The 
 
 
 
I
line 5C.C7 transgenic mice (4, 5) were backcrossed to B10.A
 
Address correspondence to Nicola L. Harris, Malaghan Institute of Medi-
cal Research, PO Box 7060, Wellington South, New Zealand. Phone: 64
4 389 5096; Fax: 64 4 389 5095; E-mail: nharris@malaghan.org.nz 
318
 
T Cell Function in Lymphoid and Nonlymphoid Tissues
 
mice and maintained by breeding transgenic males to B10.A fe-
males. The TCR used to generate the 5C.C7 transgenic strain
was derived from the cytochrome c–specific T cell clone 5C.C7.
All animal experimental procedures used in this study were ap-
proved by the Wellington School of Medicine Animal Ethics
Committee, and performed in accordance with the guidelines set
by the University of Otago (Dunedin, New Zealand). 
 
T Cell Culture, Carboxyl Fluorescein Succinimidyl Ester Labeling,
and Adoptive Transfer.
 
Naive T cells from 5C.C7 mice were pu-
rified from the lymph nodes by gradient centrifugation over 60
and 70% layered Percoll
 
®
 
 (Amersham Pharmacia Biotech), fol-
lowed by depletion of CD8
 
 
 
 T cells and B cells using Dyna-
beads
 
®
 
 (Dynal). CD4
 
 
 
 T cells were incubated on anti-CD3 mAb
(2C11, 10 
 
 
 
g/ml) coated six-well plates (Falcon; Becton Dickin-
son) in complete IMDM plus 20 U/ml recombinant human IL-2
(IL2L6 supernatant), 1,000 U/ml recombinant mouse IL-4 su-
pernatant, 10 ng/ml recombinant human IL-6 and anti-CD28
mAb (1:50 dilution of 37.51 supernatant). Complete IMDM
consisted of IMDM (Sigma-Aldrich) with 5% FCS (GIBCO
BRL), 2 mM glutamine (Sigma-Aldrich), 1% penicillin-strepto-
mycin (Sigma-Aldrich) and 5 
 
 
 
 10
 
 
 
5
 
 M 2-ME (Sigma-Aldrich).
Cells were cultured for 5–6 d with media. Floating cells were re-
moved every 2–3 d and replaced with fresh cIMDM 
 
 
 
 cytokines.
At the end of the anti-CD3 culture, plate-bound cells were re-
moved, washed extensively, and then cultured for another 3–4 d
in cIMDM 
 
 
 
 20 U/ml IL-2. After this rest period, the percent-
age of V
 
 
 
11
 
 
 
V
 
 
 
3
 
 
 
 T cells was determined by FACS
 
®
 
 analysis.
Cells were labeled with carboxyl fluorescein succinimidyl ester
(CFSE)
 
*
 
 by incubation with 5 
 
 
 
M CFSE (Molecular Probes) for
8 min at room temperature in PBS, followed by quenching of the
unlabeled CFSE with excess FCS and extensive washing. Be-
tween 5 
 
 
 
 10
 
6
 
 and 2 
 
 
 
 10
 
7
 
 CFSE
 
 
 
V
 
 
 
11
 
 
 
V
 
 
 
3
 
 
 
 T cells were in-
jected into the tail vein of sex-matched B10.A mice in a total
volume of 500 
 
 
 
l IMDM, as indicated for each experiment. Al-
ternatively 10
 
6
 
 CFSE
 
 
 
V
 
 
 
11
 
 
 
V
 
 
 
3
 
 
 
 T cells were administered in-
tranasally to naive B10.A mice in a total volume of 30 
 
 
 
l IMDM.
 
Peptide and Cytokine Challenge.
 
At the stated times after
adoptive transfer, recipient mice were anesthetized by injection
of a mixture of Ketamine and Xylazine (Phoenix), and then chal-
lenged intranasally with 100 
 
 
 
g moth cytochrome c (MCC)
 
88–103
 
in 50 
 
 
 
l PBS, or with PBS alone. Alternatively, 100 
 
 
 
g MCC
 
88–103
 
in 200 
 
 
 
l alum adjuvant (SERVA) was injected into the perito-
neum (i.p. challenge). For intranasal administration of IL-2, mice
were given an inoculation of 1,000 U recombinant human IL-2
in 50 
 
 
 
l cIMDM, or 50 
 
 
 
l cIMDM alone.
 
Bone Marrow Dendritic Cells (BMDC) Culture and Administra-
tion.
 
Bone marrow cells from B10.A mice were cultured in six-
well plates (Falcon) at 4 
 
 
 
 10
 
5
 
 cells/ml in cIMDM containing 20
ng/ml IL-4 and 20 ng/ml GM-CSF, as described previously (6).
Cultures were provided with fresh cIMDM 
 
 
 
 cytokines every
2 d and incubated at 37
 
 
 
C for a total of 7 d. BMDC (10
 
6
 
 cells/ml)
were loaded with MCC
 
88–103
 
 by incubation for 2 h at 37
 
 
 
C in
cIMDM 
 
 
 
16 
 
 
 
g/ml MCC
 
88–103
 
. Cells were washed three times
with IMDM to remove excess Ag, and then 10
 
6
 
 BMDC 
 
 
 
MCC
 
88–103
 
 administered intranasally to anesthetized mice in a to-
tal volume of 30 
 
 
 
l IMDM.
 
Lymphocyte Isolation.
 
Cell suspensions were made from
lymph node or spleen, and RBC lysed by incubation for 5 min at
 
37
 
 
 
C in 3 ml ammonium-chloride-Tris buffer. Mice used for the
preparation of lung lymphocytes were killed and the lungs per-
fused via the right ventricle of the heart with 
 
 
 
5 ml PBS to re-
move circulating blood. Minced lung tissue was incubated for
1 h in cIMDM containing 2.4 
 
 
 
g/ml collagenase type II
(GIBCO BRL) and 0.1% DNase 1 (Sigma-Aldrich), and mono-
nuclear cells purified by gradient centrifugation over 30% Per-
coll
 
®
 
. When lung and airway cells were used for in vitro culture,
macrophages were depleted by culturing cells on plastic dishes in
cIMDM for 1–2 h at 37
 
 
 
C. Alternatively, lung or liver tissue was
minced for 3 min in a Medimachine (Becton Dickinson) in
IMDM containing 0.1% DNase 1, and mononuclear cells puri-
fied by gradient centrifugation over 30% Percoll
 
®
 
. Lymphocytes
were isolated from peripheral blood by collecting 100 
 
 
 
l of tail
blood into 1 ml Alsever’s solution, followed by a 5–10-min incu-
bation in 3 ml ammonium-chloride-Tris buffer to lyse RBC.
Mononuclear cells were purified from airway by broncho-alveo-
lar lavage (BAL). BAL was performed by flushing 3 
 
 
 
 1 ml PBS
a total of five times each into the airway. Analysis of cellular infil-
tration into the airway was performed by BAL and differential
cell counting as described previously (7). Intraperitoneal wash
mononuclear cells were isolated by flushing 8 ml PBS three times
into the peritoneal cavity.
 
Flow Cytometric Analysis. 
 
FACS
 
®
 
 analysis of lymphocytes
was performed by staining as described (7). Anti-CD4 (GK1.5)
was purified from hybridoma culture supernatant, and conjugated
to biotin. Anti–V
 
 
 
11-PE or Biotin, anti–V
 
 
 
3-Biotin, anti–
CD44-PE, anti–3G-11-Biotin, anti–CD62L-PE, and Streptavi-
din-PerCP or -APC were all obtained from PharMingen. 
 
Intracellular Cytokine Detection.
 
Lymphocytes were cultured
for 2 h on uncoated, or anti-CD3 mAb (2C11, 10 
 
 
 
g/ml)
coated, 24-well plates (Falcon) in cIMDM and anti-CD28 mAb
(1/50 37.51 supernatant) at a concentration of 10
 
6
 
 cells/well.
Monensin (Calbiochem-Novabiochem) was added to the cul-
tures at a final concentration of 2 
 
 
 
M and the incubation contin-
ued for 4 h. Alternatively, lymphocytes were collected directly
into cIMDM containing 2 
 
 
 
M monensin, and then incubated at
37
 
 
 
C for 20 min without stimulation. At the end of the culture,
cells were harvested, washed once in PBS buffer, and fixed in 4%
paraformaldehyde (Sigma-Aldrich) for 15 min at room tempera-
ture. Fixed cells were washed and resuspended in FACS
 
®
 
 buffer
containing anti-Fc receptor mAb (24.G2). Indicated cells were
then surface stained with V
 
 
 
11-Biotin mAb followed by SA-
PerCP (PharMingen). After washing to remove unbound anti-
body, cells were subjected to intracellular cytokine staining in sa-
ponin buffer (PBS, 10 mM Hepes, 0.1% saponin, 0.1% BSA,
0.02% Na azide) for 30 min at room temperature. Anti–IL-4–
APC, –IL-5–PE, –IFN-
 
 
 
–APC, and –IL-2–PE were all obtained
from PharMingen and used at a 1:100 dilution.
 
Results
 
Lymph Node and Nonlymphoid Tissues Select Distinct T Cell
Populations after Adoptive Transfer of In Vitro Activated
V
 
 
 
11
 
 
 
V
 
 
 
3
 
 
 
 T Cells.
 
Activated T cells were prepared for
adoptive transfer to B10.A recipients according to the fol-
lowing protocol. Naive CD4
 
 
 
 T cells from 5C.C7 mice
were purified by gradient centrifugation over Percoll
 
®
 
 and
negative depletion using Dynabeads
 
®
 
. Between 50 to 70%
of CD4
 
 
 
 T cells from 5C.C7 mice expressed both trans-
genic V
 
 
 
11 and V
 
 
 
3 TCR chains specific for either pi-
geon cytochrome c fragment 81–104 and I-E
 
k
 
, or MCC (8,
 
*
 
Abbreviations used in this paper:
 
 BAL, broncho-alveolar lavage; BMDC,
bone marrow dendritic cells; CFSE, carboxyl fluorescein succinimidyl es-
ter; DC, dentritic cells; MCC
 
88–103
 
, moth cytochrome c fragment 88–103;
med LN, mediastinal lymph node. 
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9). The remaining CD4
 
 
 
 T cells expressed the transgenic
V
 
 
 
3 TCR chain along with an endogenously rearranged
TCR
 
 
 
 chain and did not respond to the MCC peptide
(unpublished data).
The naive 5C.C7 CD4
 
 
 
 T cells were activated with
plate-bound anti-CD3 and anti-CD28 mAb in the presence
of IL-2, IL-6, and IL-4. Cells were cultured for 5–6 d, with
floating cells removed every 2 d and replaced with fresh me-
dia plus additives. Cells were cultured for an additional 2–4 d
in IL-2 alone. At the end of this period the large majority
of harvested T cells were viable and expressed elevated levels
of CD44 (Pgp-1), and medium to low levels of CD62L (L-
selectin, Mel-14) (Fig. 1 A). These cells completely lacked
expression of 3G-11 (Fig. 1 A), a marker that is lost after the
activation of naive cells (10). If restimulated with anti-CD3,
these T cells were found to be predominantly IL-4 produc-
ers (68%), whereas a smaller number produced IL-2 (33%),
IL-5 (18%), and IFN-
 
 
 
 (19%) (unpublished data).
 
Before adoptive transfer, the activated T cells were la-
beled with CFSE (11) and injected intravenously into naive
syngenic B10.A hosts. 5 d later, cell suspensions were pre-
pared from lymph nodes, lung, and airway tissue of adop-
tive hosts. Airway cells were recovered by performing a
broncho-alveolar lavage. Lung cells included all cells re-
maining in the airways after lavage, as well as cells resident
in the lung tissue itself. Reisolated CFSE
 
 
 
V
 
 
 
11
 
 
 
V
 
 
 
3
 
 
 
 T
cells from each tissue were identified by fluorescent staining
and examined for the expression of CD44, CD62L, and
3G-11 (Fig. 1 B). CFSE
 
 
 
V
 
 
 
11
 
 
 
V
 
 
 
3
 
 
 
 T cells from the
lymph nodes, lung, and airway of adoptive hosts all dis-
played an activated phenotype (CD44
 
hi
 
, 3G-11
 
lo
 
). Cells re-
covered from the lung contained two populations that
were either CD62L
 
med
 
 or CD62L
 
lo
 
, whereas the majority
of cells recovered from the airway were CD62Llo. In con-
trast, CFSE V 11 V 3  T cells recovered from the
lymph nodes were almost all CD62Lhi.
Thus, adoptively transferred activated T cells appear to
separate into distinct subpopulations that migrate to either
lymph nodes or nonlymphoid tissues according to their
expression of high or low levels of CD62L, respectively.
In Vivo Ag Challenge Induces Clonal Expansion of Adop-
tively Transferred V 11 V 3  T Cells Migrating to the Lymph
Node, but Not Those Migrating to Nonlymphoid Tissue. We
compared the ability of previously activated V 11 V 3 
T cells to divide after contact with Ag in a lymph node,
versus contact in a nonlymphoid tissue environment. Mice
were injected intravenously with in vitro–activated CFSE 
V 11 V 3  T cells and then challenged with 100  g
MCC88–103 via the intranasal route. Intranasal challenge is a
reliable means of delivering either soluble Ag, infectious
agents, or cells to the lower airways, and results in a spe-
cific T cell response in the airways, lung, and draining me-
diastinal lymph node (med LN)(12, 13). Cell division of
the adoptively transferred CFSE V 11 V 3  T cells at
various host tissue sites was followed by FACS® analysis.
Although in vitro–activated T cells do not label with
CFSE in a sufficiently narrow peak to enable accurate
quantitation of cell division, we were able to demonstrate
that V 11 V 3  T cells in the draining med LN divided
vigorously in response to MCC88–103 intranasal challenge
(Fig. 2 A). Strikingly, V 11 V 3  T cells isolated from
the airway had not divided, even by 90 h after intranasal
Ag challenge (Fig. 2 A). Similarly, no division of V 11 
V 3  T cells from lung tissue was detected (unpublished
data). It is important to note that a small proportion
( 0.8%) of T cells in naive B10.A hosts express the V 11
and V 3 TCR chains. These cells are not specific for
MCC and can be distinguished from the adoptively trans-
ferred cells because they are CFSE negative in the FACS®
plots shown (Fig. 2 A).
The Ag-induced accumulation of V 11 V 3  T cells in
the draining med LN and airway was also determined at
various time points after intranasal challenge. A marked ac-
cumulation of V 11 V 3  T cells was observed in both
the med LN and airway of MCC88–103 intranasally chal-
lenged, but not PBS challenged, mice (Fig. 2 B). These
Figure 1. Activation marker expression by pre- and postadoptively
transferred V 11 V 3  T cells. (A) Activated T cells were generated in
vitro, and then examined for expression of CD44, 3G-11 and CD62L.
Profiles shown are for live V 11 V 3  T cells. Activation marker ex-
pression on naive peripheral blood V 11 V 3  T cells from 5C.C7 mice
is shown as a control. (B) In vitro–activated T cells were CFSE labeled,
and 2   107 CFSE V 11 V 3  T cells injected into the tail vein of naive
syngenic B10.A hosts. 2–5 d later, lymphocytes were purified from the
peripheral lymph nodes, lung, and airway, and their expression of CD44,
3G-11, and CD62L examined. Profiles shown are for live CFSE 
V 11 V 3  T cells. Numbers reflect the percentage of cells that fall
within the shown boundaries. The data shown are from one representa-
tive experiment using six to eight mice per group. Similar results were
obtained from three separate experiments.320 T Cell Function in Lymphoid and Nonlymphoid Tissues
data indicate that the MCC88–103-induced V 11 V 3  T
cell accumulation in the airway occurs solely as a result of
cellular recruitment from the blood and lymph nodes, since
T cells resident in the airway did not divide (Fig. 2 A).
Analysis of the inflammatory exudate induced by intranasal
MCC88–103 challenge also revealed that eosinophils had
been recruited to the airway (Fig. 2 C), an event dependent
on local IL-5 production by CD4  T cells (7, 14, 15). This
result indicated that airway V 11 V 3  T cells had recog-
nized Ag and were producing IL-5. No airway eosinophilia
or V 11 V 3  T cell accumulation was observed in
B10.A mice that had been intranasally challenged with
MCC88–103, and had not received in vitro–activated
V 11 V 3  T cells (unpublished data).
To further compare the function of T cells encounter-
ing Ag in either the lymph nodes or lung and airway tis-
sue, we analyzed in vivo cytokine production by adop-
tively transferred V 11 V 3  T cells after intranasal
MCC88–103 challenge. Mice were given an intranasal chal-
lenge with 100  g MCC88–103 2 d after receiving an adop-
tive transfer of in vitro–activated CFSE V 11 V 3  T
cells. 2 h after the intranasal challenge, lymphocytes were
isolated from med LN, lung, and airway tissue. Once iso-
lated, these cells were incubated for 20 min in monensin-
containing medium (without stimulation) to inhibit the
loss of any cytokines that were being synthesized in vivo at
the time of tissue removal. At the end of the incubation
period, cells were fixed and cytokine production analyzed
by intracellular cytokine staining.
The data in Fig. 3 shows the proportion of CFSE  T
cells that could produce IL-2, IFN- , or IL-4 after the in-
tranasal Ag challenge. CFSE  T cells from either the med
LN, or the lung and airway of MCC88–103 challenged mice,
were able to produce IL-2, IFN- , and IL-4. Slightly more
CFSE  T cells from the lung and airways produced IL-2 as
compared to CFSE  T cells from the med LN after intra-
nasal challenge with Ag (Fig. 3). In the experiment shown
(Fig. 3), a greater proportion of CFSE  T cells in the med
LN appeared to be producing IL-4, as compared with lung
and airway T cells. However, in other experiments this sit-
uation was reversed (unpublished data), indicating there is
some background variation.
The percentage of CFSE  T cells found to produce ef-
fector cytokines in these experiments was very low. We
believe a much greater number of CFSE  T cells are capa-
Figure 2. In vivo accumulation and division of activated V 11 V 3 
T cells in the med LN and airway of mice challenged intranasally with
MCC88–103. Activated V 11 V 3  T cells were generated in vitro, CFSE
labeled, and 5   106 CFSE V 11 V 3  T cells injected into the tail
vein of naive syngenic B10.A hosts. On that day mice were challenged
intranasally with PBS or MCC88–103. Responses were measured at indi-
cated time points after intranasal challenge. (A) Cell division was exam-
ined by FACS® analysis of CFSE intensity. Profiles shown are for live
V 11 V 3  T cells. (B) Accumulation of live V 11 V 3  T cells in the
med LN and airway of intranasally challenged mice was examined by
FACS®. (C) Eosinophil infiltration into the airway of intranasally chal-
lenged mice was examined by BAL and differential cell counting of Gi-
emsa-stained cytospins. The data shown represents mean   SE of two to
three mice per group from one representative experiment. Similar results
were obtained from three separate experiments.
Figure 3. In vivo cytokine production by activated V 11 V 3  T cells
in the med LN or lung and airway, after intranasal challenge with MCC88–103.
Activated V 11 V 3  T cells were generated in vitro, CFSE labeled, and
7.5   106 CFSE V 11 V 3  T cells injected into the tail vein of naive
syngenic B10.A hosts. The next day mice were challenged intranasally
with MCC88–103 or PBS. 2 h later mice were killed and lymphocytes from
the med LN, or lung and airway, were incubated for 20 min in cIMDM
containing 2  M monensin. T cells were then fixed and examined for ex-
pression of IL-4, IL-2, or IFN-  using intracellular cytokine staining. Pro-
files shown are for CFSE  T cells. The data shown represents mean   SE
of three mice per group from one representative experiment. Similar re-
sults were obtained from three separate experiments.321 Harris et al.
ble of producing effector cytokines in the lung, airway, and
med LN, but that these are not detected by the intracellular
cytokine staining protocol for ex vivo T cells. Indeed we
found no IL-5 production in any of the experiments per-
formed. This likely reflects a poor sensitivity of the intra-
cellular cytokine staining protocol used, as the Ag-depen-
dent eosinophilia indicated that significant IL-5 production
was occurring in the airways. Our results contrast with
those of Lee Reinhardt et al. (16) who reported that pro-
duction of the effector cytokine IFN-  is largely confined
to the nonlymphoid tissues. However, these authors were
investigating memory T cells, and the experimental proto-
col used involved the coadministration of LPS, which
could have significant effects on T cell activation and recir-
culation patterns. Furthermore, our analysis of IL-4 expres-
sion supports our finding that effector cytokines can be
produced in lymph node.
Taken together, our data demonstrates that previously
activated T cell populations resident in nonlymphoid tis-
sues, such as the lung and airway, do not divide and do not
clonally expand when activated by Ag (Fig. 2 A). How-
ever, these T cells are not anergic as they are able to pro-
duce cytokines (Fig. 3) and initiate profound inflammatory
cell exudates in the airway (Fig. 2 C). By contrast, previ-
ously activated T cells resident in the draining lymph node
undergo rapid cell division after Ag challenge (Fig. 2 A).
These lymph node–homing T cells also produce effector
cytokines (Fig. 3).
Reisolated Lung and Airway V 11 V 3  T Cells Can Di-
vide In Vitro. We questioned whether the lack of detect-
able division by Ag-challenged T cells in the airway was
an intrinsic property of those T cells. In vitro–activated
CFSE V 11 V 3  T cells were adoptively transferred
into naive hosts, and then recovered from the peripheral
lymph nodes, lung, and airway, without additional in vivo
Ag challenge. These cells were then cultured with T cell–
depleted splenocytes from naive B10.A mice   10  g/ml
MCC88–103. Cell division was detected by recording the
changes in CFSE intensity. Reisolated CFSE V 11 V 3 
T cells from all tissues could divide in response to MCC88–103
stimulation in vitro (Fig. 4 A). In each of the experiments,
previously activated T cells reisolated from the lung and
airway were found to divide at a slightly faster rate than
those reisolated from peripheral lymph nodes (Fig. 4 A and
unpublished data). All the T cells from the lung and airways
appeared to divide in vitro.
The ability of reisolated CFSE V 11 V 3 T cells to
produce cytokines after reactivation in vitro was also exam-
ined. Lymphocytes were isolated from lymph nodes, lung,
and airway, and stimulated for 6 h on plate-bound anti-
CD3 plus anti-CD28 mAb. Monensin was added for the
last 4 h of culture, after which cells were fixed in 4%
paraformaldehyde. The production of IL-4, IL-5, IL-2, or
IFN-  by the reisolated CFSE V 11 V 3  T cells was
examined by intracellular cytokine staining. The data pre-
sented in Fig. 4 B demonstrate that CFSE V 11 V 3  T
cells from either the lymph nodes, or lung and airway, can
produce IL-4, IFN- , and IL-2. For each of these cyto-
kines a slightly larger proportion of CFSE V 11 V 3  T
cells from the lung and airway were cytokine positive, as
compared with those from the lymph nodes (Fig. 4 B). Us-
ing this technique, IL-5 producing CFSE V 11 V 3  T
cells could only be detected in small numbers, and only in
the lung (Fig. 4 B).
In summary, our data indicate that activated T cells
present in the lung and airway are more sensitive to Ag
stimulation in vitro (as measured by division and cytokine
production) than those from the lymph nodes. Our find-
ings also indicate that it is the microenvironment of the
lung and airway that prevents T cell division in vivo (Fig. 2
A), since the inability to divide is not an intrinsic property
of the T cells present at these sites.
Immunization With Peptide-loaded BMDC Cannot Induce
Division of Airway Resident V 11 V 3  T Cells. We
considered it likely that the environmental factor limiting
T cell division in the lung and airway was APC function.
Although dendritic cells (DC) are considered to be the
most potent lung APC (17, 18), numerous studies (19, 20)
have shown that lung DC exhibit an immature phenotype
Figure 4. In vitro division and cytokine production by activated
V 11 V 3  T cells reisolated from the lymph nodes, or lung and airway.
Activated V 11 V 3  T cells were generated in vitro, CFSE labeled, and
2   107 CFSE V 11 V 3  T cells injected into the tail vein of naive
syngenic B10.A hosts. 2–5 d later lymphocytes were purified from the pe-
ripheral lymph nodes, and lung and airway. (A) 5   105 lymph node, or
lung and airway, cells were cultured with 1.5   106 T cell–depleted sple-
nocytes from naive B10.A mice   10  g/ml MCC88–103. After 48 h of
culture, T cell division was examined by FACS® analysis of CFSE inten-
sity. Profiles shown are for live V 11 V 3  T cells. (B) Peripheral lymph
node, or lung and airway, T cells were restimulated with anti-CD3 and
anti-CD28 in the presence of 2  M monensin for 6 h. T cells were then
examined for expression of IL-4, IL-5, IL-2, or IFN-  using intracellular
cytokine staining. Profiles shown are for CFSE V 11 V 3  T cells. In
both A and B, lung represents lung and airway cells. The data shown are
from representative experiments, using six to eight mice per group. Each
experiment was repeated two to three times with similar results.322 T Cell Function in Lymphoid and Nonlymphoid Tissues
with a low level of expression of MHC class II and costim-
ulatory molecules. In our laboratory we routinely generate
in vitro–cultured bone marrow DC (BMDC) that exhibit a
mature phenotype, and express high levels of MHC class II
and B7–1 (unpublished data). Lambrecht et al. and Ha-
venith et al. have shown that DC delivered via the intratra-
cheal route can activate naive T cells present in the med
LN (13, 21). In addition, we found that CFSE-labeled
BMDC delivered intranasally could later be isolated from
the lung and med LN tissues, indicating their ability to es-
tablish in the airway and to further migrate to local lymph
nodes (unpublished data).
To test whether the lack of T cell division in the lung
and airway was due to poor APC function by airway resi-
dent DC, we challenged mice with in vitro–generated
BMDC presenting MCC88–103. As shown in Fig. 5 A, Ag-
loaded BMDC induced vigorous division of CFSE 
V 11 V 3  T cells in the med LN. However, no division
of airway CFSE V 11 V 3  T cells was observed at 50
or 66 h after intranasal challenge. It is important to note
that at the 90-h time point we observed the appearance of
CSFEdull V 11 V 3  T cells in the airway (Fig. 5 A). The
level of CSFE staining in the 90-h airway population was
comparable to that seen in the med LN at 66 h (Fig. 5 A).
This suggested that the CSFEdull T cells present in the air-
way at 90 h had been recently recruited from the med LN,
and were not resident airway T cells that had divided. In-
terestingly, the adoptively transferred CFSE V 11 V 3 
T cells had undergone several rounds of division in the
med LN of the PBS-challenged mice at 66 h. Although this
phenomenon did not occur consistently throughout the
experiments, it suggests that in vitro–activated T cells may
be capable of dividing in vivo in the absence of Ag. This
may reflect the activity of homeostatic mechanisms operat-
ing to maintain memory T cells. Taken together, these data
indicate that the lack of division observed for airway
V 11 V 3  T cells in Fig. 2 A, cannot be overcome by
Ag presentation on BMDC. This suggests that lack of cell
division in the airway is not simply a result of reduced air-
way APC function.
To evaluate whether donor DC transferred Ag to host
DC, a separate group of mice were challenged with etha-
nol-killed BMDC   MCC88–103. Ethanol-fixed BMDC
expressed levels of MHC class II that were equivalent to
that seen for live BMDC. The conditions used to fix the
BMDC were adjusted to avoid the loss of peptide from
MHC class II molecules. Intranasal delivery of live BMDC  
MCC88–103 induced the accumulation of V 11 V 3  T
cells in both the med LN and the airway (Fig. 5 B). It also
led to the development of a profound airway eosinophilia
(Fig. 5 C). These responses were not observed after intra-
nasal administration of ethanol-killed BMDC   MCC88–103
(Fig. 5, B and C), indicating that MCC88–103 presentation
occurs exclusively by the donor BMDCs.
Exogenous IL-2 Cannot Restore Division of Airway Resident
V 11 V 3  T Cells. The lack of division of T cells in
the airway did not appear to be due to poor airway APC
function. We speculated that it could instead be caused by
limited local IL-2 production. We have shown in Fig. 3
that CFSE V 11 V 3  T cells in the lymph node, lung,
and airway, all produced similar levels of IL-2 after intrana-
sal Ag challenge. Nevertheless, it was possible that by-
stander IL-2 production was confined to the lymph node
environment. Therefore, to address the possibility of IL-2
deficiency in the lung environment, we delivered large
doses of exogenous IL-2 to the airway of mice. The same
mice were also given CFSE V 11 V 3  T cells  
MCC88–103 via the intranasal route.
Intratracheal adoptive transfer of lung memory CD4  T
cells has already been shown by Hogan et al. (22) to result
in a functional population of cells that remain in the air-
way for several weeks after transfer. In our experiments,
intranasal adoptive transfer of in vitro–activated CFSE 
V 11 V 3  T cells resulted in a population of airway-
resident T cells that were viable and could respond to in-
tranasal-delivered Ag by producing IL-5 and generating an
airway eosinophilia (Fig. 6 B). At day 4 after intranasal
Figure 5. Effect of intranasal challenge with BMDC   MCC88–103 on
division of adoptively transferred V 11 V 3  T cells. Activated
V 11 V 3  T cells were generated in vitro, CFSE labeled, and 5   106
CFSE V 11 V 3  T cells injected into the tail vein of naive syngenic
B10.A hosts. On that day mice were challenged intranasally with 106 eth-
anol-killed or live BMDC   MCC88–103. Responses were measured at in-
dicated time points after intranasal challenge. (A) The extent of cell divi-
sion was examined by FACS® analysis of CFSE intensity. Profiles shown
are for live V 11 V 3  T cells (B) Accumulation of live V 11 V 3  T
cells in the med LN or airway of intranasally challenged mice was exam-
ined by FACS®. (C) Eosinophil infiltration into the airway of intranasally
challenged mice was enumerated by BAL and differential cell counting of
Giemsa-stained cytospins. The data shown represent mean   SE of three
to four mice per group from one representative experiment. Similar re-
sults were obtained in two to four separate experiments.323 Harris et al.
adoptive transfer,  20% of input CFSE  T cells could be
recovered from the airway by broncho-alveolar lavage
(BAL). In addition, a significant population of viable
CFSE  T cells that were not isolated by BAL, could be
identified in lung and airway tissue that had been subjected
to collagenase digestion (Fig. 7 A).
Despite being able to generate an airway eosinophilia af-
ter MCC88–103 stimulation, CFSE V 11 V 3  T cells ad-
ministered to the airways remained undivided even 4 d af-
ter Ag challenge (Fig. 6 A). The addition of exogenous IL-2
to the airway was not found sufficient to restore cell divi-
sion (Fig. 6 A). However, IL-2 resulted in a large increase
in the number of airway eosinophils seen after MCC88–103
stimulation (Fig. 6 B). This indicates that the adoptively
transferred T cells were capable of responding to IL-2 by
producing increased amounts of IL-5. These data verify our
earlier observations that previously activated T cells present
in the airway do not divide, and indicate that this is not due
to a lack of IL-2 production.
Airway Resident V 11 V 3  T Cells Do Not Return To
the Circulation. One of the surprising findings of this study
was that while undivided, CFSEbright V 11 V 3  T cells
were abundant in the airway at all time points, undivided
cells were lost from the med LN by 50 h and did not return
(Fig. 5 A). We hypothesized that T cells in the airway were
unable to recirculate back to the draining lymph node,
even when it was inflamed.
To test this hypothesis, mice were intranasally adminis-
tered with in vitro–activated CFSE V 11 V 3  T cells.
This population contains T cells that are capable of migrat-
ing to the lymph node and nonlymphoid tissues after intra-
venous injection (Fig. 1). 4 d after intranasal transfer of
CFSE V 11 V 3  T cells, relevant tissues were exam-
ined for the presence of V 11 V 3  T cells, and the num-
ber of these cells that were CFSE  determined. As ex-
pected from the previous data, all the V 11 V 3  T cells
recovered by lavage from the airway of nonimmunized
Figure 6. In vivo division of intranasally administered, activated
V 11 V 31 T cells, after intranasal challenge with MCC88–103   IL-2.
Activated V 11 V 3  T cells were generated in vitro, CFSE labeled,
and 106 CFSE V 11 V 3  T cells administered intranasally to naive
syngenic B10.A hosts. On that day mice were challenged intranasally
with PBS or MCC88–103. At days 0 and 2 after challenge, mice were addi-
tionally treated with an intranasal inoculation of 500 U rhIL-2 in cIMDM,
or cIMDM alone. (A) On day 4 after MCC88–103 intranasal challenge, cell
division was examined by FACS® analysis of CFSE intensity. Profiles
shown are for live V 11 V 3  T cells. (B) Accumulation of eosinophils
in the airway 4 d after MCC88–103 intranasal challenge was determined by
BAL and differential cell counting of Giemsa-stained cytospins. The data
shown represents the mean   SE of three to four mice from one repre-
sentative experiment. Similar results were obtained from two to four
separate experiments.
Figure 7. Migration of intranasally administered, activated V 11 
V 3  T cells. Activated V 11 V 3  T cells were generated in vitro,
CFSE labeled, and 106 CFSE V 11 V 3  T cells administered intrana-
sally to naive syngenic B10.A hosts. (A) 4 d later lymphocytes were iso-
lated from the airway, lung, med LN, mes LN, liver, and spleen. (B) Al-
ternatively, recipient mice were immunized intraperitoneally with 100  g
MCC88–103 in 200  l alum adjuvant, and lymphocytes isolated from the
airway, spleen, and peritoneal cavity at days two and four after immuniza-
tion. Profiles shown are for live V 11 V 3  T cells. The data shown are
from representative experiments, using three mice per group. Each exper-
iment was repeated two to four times with similar results.324 T Cell Function in Lymphoid and Nonlymphoid Tissues
mice were CFSE  (Fig. 7 A). The majority of V 11 V 3 
T cells found in the lung were also CFSE . In contrast, no
V 11 V 3  T cells recovered from the draining med LN,
mesenteric LN, or spleen, were CFSE  (Fig. 7 A). Nor
were any CFSE V 11 V 3  T cells found in the liver, an
organ that has been suggested to act as a “graveyard” for
activated T cells (23).
We were concerned that CFSE V 11 V 3  T cells
that left the airway might have been distributed to systemic
tissues in numbers below our threshold of detection. To
address this possibility we challenged mice with MCC88–103
in alum adjuvant via the intraperitoneal route. Intraperito-
neal immunization of naive or primed mice results in Ag
drainage to the spleen (24), and an accumulation of Ag-
specific T cells in both the peritoneum and spleen (unpub-
lished data). Therefore, any CFSE V 11 V 3  T cells
present in the circulation after intranasal inoculation should
be recruited to the peritoneum and spleen after intraperito-
neal MCC88–103–alum challenge. At days 2 and 4 after in-
traperitoneal Ag challenge, we examined the spleen and
peritoneal cavity of mice that had received an intranasal
transfer of CFSE V 11 V 3  T cells. No CFSE 
V 11 V 3  T cells were detected in either the spleen or
the peritoneum at day 2, before any cell division would be
expected to occur, or day 4, after intraperitoneal challenge
with MCC88–103 in alum (Fig. 7 B).
In summary, these data indicate that adoptively trans-
ferred CFSE V 11 V 3  T cells immigrating to the lung
and airway are unable to recirculate to other tissue sites,
even after specific Ag challenge. Together these data sup-
port our hypothesis that previously activated T cells resi-
dent in (or recruited to) the lung and airway are unable to
return to the lymph node or recirculating pool.
Discussion
Adoptively transferred CFSE-labeled in vitro–activated
T cells were found to separate into distinct subpopulations
based on their migration to lymph node, lung, or airway
tissue. Although we have no understanding of what in vitro
factors determine the commitment of naive T cells into
each of the activated T cell subpopulations, their migration
into lymph nodes correlated with higher levels of expres-
sion of CD62L. CD62L is known to be important for lym-
phocyte entry into lymph nodes (25), and acts as a ligand
for MAdCAM-1 that is expressed on high-walled endothe-
lium of the lymph node (26). Our subpopulations of acti-
vated T cells closely resemble the proposed TEM and TCM
subpopulations of memory T cells proposed by Sallusto et
al. (27), with respect to their expression of CD62L. This
resemblance in terms of CD62L expression may be ex-
plained by the finding that TEM and TCM subpopulations of
memory T cells also reside in nonlymphoid or lymphoid
tissues, respectively (16, 28). CCR7, a chemokine receptor
expressed by naive and central memory (TCM) T cells (27),
also controls homing to secondary lymphoid tissues and
may be expressed by T cells found to enter lymph node in
our experiments.
We compared the functions of the adoptively transferred
CFSE  T cells that migrate to the lymph node, with
CSFE  T cells that migrate to nonlymphoid tissues such as
the lung and airway. CFSE  T cells present in either the
lymph nodes, or the lung and airway, could all produce
similar levels of cytokines after encountering MCC88–103 in
vivo (Fig. 3). CFSE  T cells in the med LN also divided
vigorously in response to MCC88–103 (Fig. 2 A). In striking
contrast, CFSE  T cells in the lung and airway could not
be induced to divide upon exposure to MCC88–103 (Fig. 2
A and unpublished data). However, CFSE  T cells reiso-
lated from either the lymph nodes, or the lung and airway,
could divide extensively when restimulated with Ag during
in vitro culture (Fig. 4 A). Therefore, the inability to divide
is not an intrinsic property of T cells that go to the lung,
but is likely to be due to the microenvironment of the lung
and airway not being supportive for T cell division.
We endeavored to determine the reason for the lack of
in vivo division observed for T cells in the lung and airway.
To our surprise, MCC88–103 presentation by donor-mature
BMDC could not induce CFSE  T cells in the airway to
divide (Fig. 5 A), although an IL-5–dependent airway eosin-
ophilia was observed (Fig. 5 C). These data strongly indi-
cate that it is not the poor T cell costimulatory function,
nor inadequate Ag processing and presentation, of lung and
airway APC that is responsible for the absence of T cell di-
vision and clonal expansion. Nor was this lack of division
found to be the result of limited IL-2 production in the
lung environment, since the addition of large amounts of
IL-2 could not induce intranasally delivered CFSE  T cells
to divide (Fig. 6 A).
There are several reports that indicate that alveolar mac-
rophages are able to suppress T cell division in vitro (for
review see 29). These findings were also extended to lung
immune responses (30). In two separate studies, it was
demonstrated that alveolar macrophages could mediate this
suppressive effect on proliferation through modification of
the signaling properties of the IL-2 receptor (31, 32). This
effect was found to be mediated by nitric oxide (33, 34).
Our results extend these in vitro findings by reporting the
key observation that the airway environment does not af-
fect the production of effector cytokines. Although we
have not resolved whether the absence of T cell division in
the airway is mediated through nitric oxide, there are sev-
eral other candidate mediators and cytokines, such as IL-10
and TGF- , which could exert this effect. Alternatively,
agents that induce production of pro-inflammatory cyto-
kines, or that have mitogenic properties, may be required
for the proliferation of lung and airway T cells. Lastly, fac-
tors (other than IL-2) that normally support T cell division
in the lymph nodes may be absent from the lung and air-
way. We are currently investigating all these possibilities in
an attempt to further define the mechanism by which the
suppression of T cell proliferation in the lung and airway
occurs. The question of the physiological significance of
the inability of T cells to divide in the lung and airway
raises some intriguing possibilities. An important consider-
ation is that suppression of T cell division in peripheral tis-325 Harris et al.
sues may serve to prevent potentially pathological T cell
activation in response to harmless environmental Ag. Ad-
ditionally, the development of cross-reactive autoimmu-
nity by pathogen-activated T cells in response to seques-
tered tissue Ag would be avoided in tissue environments
where division is prevented.
Our data indicates that activated T cells cannot divide in
the lung or airway, although cells that have divided can en-
ter these tissues after exiting the lymph node. We posed the
question as to whether these airway-homing T cells can
migrate from the airway back to the lymph node or general
circulation. The data presented in Fig. 7 indicates that
CFSE  T cells delivered to the airway do not return to the
recirculating pool. This failure to migrate out of the airway
and lung tissue is likely to be due to an inability of these
cells to move across epithelial barriers or into draining-
afferent lymphatics. It is not due to the inability of the in-
tranasally transferred cells to survive in the airway microen-
vironment, since these cells were shown to respond to Ag
and induce an airway eosinophilia (Fig. 6 B). It is interest-
ing to note that although intranasally administered, acti-
vated T cells cannot leave the airway, BMDC administered
intranasally are capable of migrating to the draining med
LN and inducing a response here (unpublished data and
13). Our data appears to contrast that of Mackay et al. who
reported the presence of CD4  T cells (35) exhibiting a
memory phenotype (3) in popliteal-afferent lymph. We do
not rule out the possibility that activated T cells leave other
nonlymphoid tissue sites to enter afferent lymphatics and
return to the lymph node. However, it would appear that
this is not the fate of the large majority of activated T cells
resident in the lung and airway.
In the context of devising vaccine strategies or immuno-
therapeutic interventions, one key implication of our work
is that the extent and degree of T cell accumulation at an
inflammatory site is tightly regulated by two distinct
events. The first is the amplification of T cell number by
expansion in the lymph node. The second involves re-
cruitment of T cells to the site of Ag exposure. There is no
apparent on-site amplification of the T cell response. In
addition, we found that the cells that migrate to the airway
are lost to this site, and fail to return to the recirculating
pool. Thus, previously activated T cells that have entered
the airway appear to be trapped, and must either remain in
the airway as long-lived cells or be lost to the mucosal sur-
face. This finding raises the possibility that resting memory
T cells may suffer the same fate. The question as to
whether memory T cells can recirculate, or whether they
form two populations destined solely for lymphoid or
nonlymphoid tissues, has important implications for our
understanding of secondary immune responses and re-
quires further investigation.
Our studies have focused on the lung, airway and drain-
ing mediastinal lymph node, and on an acute immune re-
sponse. It remains to be determined whether the observa-
tions we have made are relevant to other nonlymphoid
tissues. It would also be of considerable interest to investi-
gate whether chronic infections and/or autoimmune dis-
eases are subject to the same control mechanisms. Experi-
mental evidence suggests that chronic inflammation
involves ectopic formation of de novo lymphoid structures
(for reviews see 36, 37) that may allow T cell division to
occur. Formation of de novo lymphoid structures occurs in
infectious diseases such as Helicobacter pylori–induced gastri-
tis (38) and in autoimmune disorders including Hashi-
moto’s thyroiditis (39), rheumatoid arthritis (40, 41), Sjo-
gren’s syndrome (42), and experimental murine diabetes
(43). It is also not clear what physiological controls exist
that prevent activated T cells from dividing in the lung and
airway tissues. Elucidation of such mechanisms would have
clear potential for the development of new therapeutics.
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